NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. The shareholders of Asarina Pharma AB… Read More »NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (publ)
Peter Nordkild, CEO: “We enter the new financial year with renewed energy and optimism after Region Hovedstaden finally signed the required papers for our clinical… Read More »Asarina Pharma AB (publ) Year-end Report 2021 released
(Stockholm, 16 February, 2022.) Asarina Pharma announces today that ‘First Patient First Visit’ has taken place in its phase IIa clinical study in Tourette syndrome… Read More »First patient in for landmark Tourette Syndrome study
(Stockholm, Sweden, 22 December, 2021.) The Capital Region of Denmark (Region Hovedstaden) has now given official approval to Asarina Pharma to begin its phase IIa… Read More »Asarina Pharma receives final approval for landmark phase IIa Tourette study
Asarina Pharma CEO Peter Nordkild: “While we made progress in several areas during Q3 2021, it was frustrating for us that our phase IIa study… Read More »Asarina Pharma AB (publ) Q3 Report 2021 released
(Stockholm, 28 September 2021.) The publication of Asarina Pharma’s phase IIb study, including a post hoc analysis into Sepranolone for PMDD (Premenstrual dysphoric disorder), demonstrates… Read More »PMDD Phase IIb study, including post-hoc analysis showing ‘significant treatment effect’, published in Journal of Psychoneuroendocrinology
(Stockholm, 16 September, 2021.) An administrative backlog due to Covid-19 at The Capital Region of Denmark (Region Hovedstaden) is causing a delay of approx. 3… Read More »Administrative backlog at public authority causes short-term delay in Tourette study
Asarina Pharma CEO Peter Nordkild: “Q2 2021 was a difficult quarter for us and our shareholders. It was also a definitively transformative one. The failure… Read More »Asarina Pharma AB (publ) Q2 Report 2021 released
Asarina Pharma AB (publ) (ASAP: FN Stockholm) today releases topline results from its Phase IIa study of Sepranolone for the treatment of menstrual migraine. While… Read More »Asarina Pharma reports topline results in Phase IIa Menstrual Migraine study
(Stockholm, 8 June 2021.) The US Patent and Trademark Office has granted a patent for Sepranolone for the treatment of Tourette, Obsessive-Compulsive Disorder (OCD) and… Read More »Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling